SATB2 and colorectal adenocarcinoma: According to Magnusson et al., using SATB2 as a solitary marker, SATB2 was positive in 83.7% of stage III/IV colorectal adenocarcinomas, 91.4% of stage II and 92.4% of stage I of this malignancy.